Redesigning the Antibiotic Market for Survival: How Artificial Intelligence May Address the Economic Failure in Combating Antimicrobial Resistance

Antimicrobial resistance (AMR) represents one of the most severe global health crises of the twenty-first century, responsible for roughly 1.27 million direct deaths in 2019 and projected to cause 1.91 million attributable deaths annually by 2050. Yet no genuinely new class of antibiotics has reached patients in over three decades, not because the science has failed, but because the market has. The inverted incentive logic of antibiotic development, in which the most medically valuable drugs are deliberately rationed and modestly priced, renders the category commercially unsustainable. This essay argues that generative artificial intelligence offers a structural solution to this impasse by fundamentally compressing discovery costs and enabling a licensing-based platform business model that decouples commercial sustainability from the revenue constraints inherent to antibiotic sales. Drawing on recent empirical breakthroughs, the essay demonstrates that the technology underpinning this model has already been validated. The proposed platform architecture resolves the three structural contradictions, namely prohibitive discovery costs, concentrated revenue risk, and thin pipelines, that have driven major pharmaceutical firms out of antibiotic research.